StarMed clinical evidence

Published studies on the StarMed range of CPAP and NIV respiratory hoods. For more information on the full StarMed range, including information sheets, videos and enquiries, please visit https://www.intersurgical.com/info/starmed

Helmet CPAP to Treat Acute Hypoxemic Respiratory Failure in Patients with COVID-19: A Management Strategy Proposal

Radovanovic D, Rizzi M, Pini S, Saad M, Chiumello DA, Santus P. J Clin Med. 2020;9(4):1191

The author of this research study proposes a management strategy for the treatment of acute hypoxemic respiratory failure in patients with COVID-19. Respiratory support with NIV or high flow oxygen should be avoided to limit droplets/virus aerosolisation and healthcare worker contamination. Therefore, the implementation of CPAP through a helmet system may provide an effective and safer alternative to improve hypoxemia. In addition, the use of the helmet will also reduce room contamination and improve patient comfort, while guaranteeing better clinical assistance and long term tolerability. However, careful CPAP titration must be provided to better optimise the recruitment of unventilated lung sections to improve patient outcomes.

 

The ‘‘helmet bundle” in COVID-19 patients undergoing non-invasive ventilation

Lucchini A, Giani M, Isgrò S, Rona R, Foti G. Intensive Crit Care Nurs. 2020;58:102859

The COVID-19 outbreak represents a new challenge for intensive care teams, and of particular importance is the limitation of virus aerosolisation during intubation, bronchoscopy and non-invasive ventilation. As a result, the use of helmet ventilation has been suggested for CPAP and pressure support ventilation to reduce the spread of the virus. This letter suggests a helmet CPAP bundle to improve the patient’s comfort during extended applications by reducing the noise with an HME filter, using counterweights attached to armpit straps to avoid discomfort , as well as implementing active humidification.

Link to abstract.

 

Prophylactic use of helmet CPAP after pulmonary lobectomy: a prospective randomized controlled study

Barbagallo M, Ortu A, Spadini E, Salvadori A, Ampollini L, Internullo E, Ziegler S, Fanelli G. Respir Care. 2012 Sep;57(9):1418-24

Randomised trial of 50 patients allocated to receive either continuous oxygen therapy or two cycles of helmet CPAP for 120 minutes. Results suggest that by the end of the second helmet treatment, patient's had a significantly higher PaO2/FiO2 but the improvement in oxygenation was not lasting. However, helmet CPAP was 'secure and well tolerated'.

Link to abstract.

Helmet continuous positive airway pressure vs oxygen therapy to improve oxygenation in community-acquired pneumonia: a randomized, controlled trial

Cosentini R, Brambilla AM, Aliberti S, Bignamini A, Nava S, Maffei A, Martinotti R, Tarsia P, Monzani V, Pelosi P.
Chest. 2010 Jul;138(1):114-20

Multi-centre, randomised controlled trial. 47 patients admitted to ED with moderate hypoxemic acute respiratory failure (ARF) due to community-acquired pneumonia (CAP) were split into helmet CPAP or standard oxygen therapy groups. Primary end point was time to reach PaO2/FiO2 ratio > 315. The proportion of patients who reached the primary end point was also recorded. Authors conclude that CPAP delivered by helmet rapidly improves oxygenation in this scenario.

Link to abstract.